Ear Disorder Venture

Coming – June 25

A Novel, Non-Invasive Platform for Tinnitus and Hearing Loss

Date and Time

June 25

–

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Tinnitus and hearing loss affect more than 125 million people across the United States and Europe alone, representing a substantial and largely underserved market with limited treatment options. Most current therapies focus on symptom management and often require invasive administration procedures.

Ear Disorder Venture (EDV) is developing a proprietary non-invasive drug delivery platform designed to transport therapeutics directly to the inner ear via ear drops. The technology has the potential to transform treatment paradigms across multiple inner-ear disorders while significantly improving patient experience.

EDV represents an opportunity to participate in the development of a platform technology addressing one of the largest unmet needs in hearing health.

Join our online event with EDV CEO, Alain Moussy, to hear why their technology has the potential to transform treatment paradigms across multiple inner-ear disorders while significantly improving patient experience.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.